OI Ljubljana
Sl

Programs and Projects supported by the Slovenian Research Agency

The majority of researches carried out at the Institute are supported financially by the Slovenian Research Agency (ARRS). Comprehensive studies are carried out within research programs and targeted studies within research projects.

Research projects

CodeProject titlePeriodPrincipal Investigator at the Insitute of Oncology
N3-0059 Plasma-assisted wound treatment and topical introduction of molecules acad. prof. Gregor Sersa PhD
V3-1638 Development and implementation of personalised breast cancer risk evaluation tool for Slovenian population Vesna Zadnik PhD
V3-1713 Comprehensive analysis of management of urological cancer patients with an assessment of possible delays in referrals, realization of diagnostics procedures and first treatment 2018 - 2020prof. dr. Vesna Zadnik
V3-1718 Health risk assessment for exposures of children to low-frequency electric and magnetic (EM) fields in Slovenia 2018 - 2020prof. dr. Vesna Zadnik
V3-1720 Analysis and estimation of requirements of human resources for cancer treatment in Slovenia 2018 - 2020prof. dr. Branko Zakotnik
J3-7272 Methods od estimation of key indicators in population cancer survival Maja Primic Zakelj PhD
J3-7272 Methods of estimation of key indicators in population cancer survival 2016 - 2018prof. dr. Vesna Zadnik
J3-7372 Molecular biomarkers and biomarker-driven therapy in lung cancer Viljem Kovac PhD
J3-7460 Irradiation dose modifying factor od scuamous cell carcinoma of the oropharynx infected by human papillomavirus: as in vitroand in vivo study in laboratory mouse tumor model Primoz Strojan PhD
J3-7494 Tunneling nanotubes for innovative urinary bladder cancer treatment Maja Cemazar PhD
L2-7550 Elecrospun nanofibrous materials for solid state drug delivery system acad. prof. Gregor Sersa PhD
J1-8140 Endocrine disrupting and genotoxic potential of protein kinase inhibitors: relevance for environmental hazard prof. dr. Maja Čemažar
J3-8202 Time-lapse intra-vital imaging of immune response after electrochemotherapy induced in situ vaccination and interleukin-12 gene therapy boost prof. dr. Maja Čemažar
L3-8203 Serum, genetic and epigenetic markers of risk for developing, progress and treatment response in asbestos related diseases doc. dr. Viljem Kovač
J3-8210 Potential of low, sub-therapeutic doses of statins and sartans in primary and secondary cardiovascular disease prevention znan. svet. dr. Srdjan Novaković
J4-8227 Cathepsin X inhibitors impair the resistence of tumor cells to antiprotease therapy akad. prof. dr. Gregor Serša
J2-9225 Non-invasive technique for Cell Membrane Permeabilization using pulsed electromagnetic fields 1. 7. 2018 - 30. 6. 2021dr. Damijan Miklavčič / akad. prof. dr. Gregor Serša
J3-9269 Clinico-pharmacological approach to optimize the therapeutic bleomycin concentration in patients undergoing electrochemotherapy 1. 7. 2018 - 30. 6. 2021akad. prof. dr. Serša Gregor

Infrastructure programs

CodeProgramme titlePeriodPrincipal Investigator at the Insitute of Oncology
IP-0302 Lifelong Follow-Up of Survivors of Childhood and Adolescent Cancer and Related Translational Trials Lorna Zadravec Zaletel PhD

 

 

© 2018 - Onkološki inštitut Ljubljana